CoChat
Sign Up
Cited by 236MicroRNA in disease regulationAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease

Open access
Denk, Johannes, Boelmans, Kai, Siegismund, Christine, Lassner, Dirk, Arlt, Sönke, Jahn, Holger·2015·PLOS ONE
DOI 10.1371/journal.pone.0126423PMC PMC4439119
Open this paper in CoChat — free accountOpen PDF

Abstract

The miRBase-21 database currently lists 1881 microRNA (miRNA) precursors and 2585 unique mature human miRNAs. Since their discovery, miRNAs have proved to present a new level of epigenetic post-transcriptional control of protein synthesis. Initial results point to a possible involvement of miRNA in Alzheimer's disease (AD). We applied OpenArray technology to profile the expression of 1178 unique miRNAs in cerebrospinal fluid (CSF) samples of AD patients (n = 22) and controls (n = 28). Using a Cq of 34 as cut-off, we identified positive signals for 441 miRNAs, while 729 miRNAs could not be detected, indicating that at least 37% of miRNAs are present in the brain. We found 74 miRNAs being down- and 74 miRNAs being up-regulated in AD using a 1.5 fold change threshold. By applying the new explorative "Measure of relevance" method, 6 reliable and 9 informative biomarkers were identified. Confirmatory MANCOVA revealed reliable miR-100, miR-146a and miR-1274a as differentially expressed in AD reaching Bonferroni corrected significance. MANCOVA also confirmed differential expression of informative miR-103, miR-375, miR-505#, miR-708, miR-4467, miR-219, miR-296, miR-766 and miR-3622b-3p. Discrimination analysis using a combination of miR-100, miR-103 and miR-375 was able to detect AD in CSF by positively classifying controls and AD cases with 96.4% and 95.5% accuracy, respectively. Referring to the Ingenuity database we could identify a set of AD associated genes that are targeted by these miRNAs. Highly predicted targets included genes involved in the regulation of tau and amyloid pathways in AD like MAPT, BACE1 and mTOR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0126423

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Volcano plot of group comparisons. Comparisons of 199 miRNAs assessed in OpenArray analysis of smallRNA isolated from CSF of patients with AD (n = 22) and controls (n = 28). The volcano plot displays the relationship between fold change and significance between the two groups, applying a student’s t-test. The y-axis depicts the negative log10 of p-values of the t-tests (the horizontal slider at 1.3 corresponds to a p-value of 0.05, a higher value indicates greater significance) and the x-axis is the difference in expression between the two experimental groups as log2 fold changes (vertical sliders indicate miRNAs as either up- or down regulated above a fold change of 1.5). Highlighted in green are the most reliable (6 abundant miRNAs from set A with RF≥0.8) and in red the most informative (9 less abundant miRNAs from set B above the critical MoR value d = 0.57) biomarkers according to the MoR-method (see Figs 2 and 3).
Fig 1 Volcano plot of group comparisons. Comparisons of 199 miRNAs assessed in OpenArray analysis of smallRNA isolated from CSF of patients with AD (n = 22) and controls (n = 28). The volcano plot displays the relationship between fold change and significance between the two groups, applying a student’s t-test. The y-axis depicts the negative log10 of p-values of the t-tests (the horizontal slider at 1.3 corresponds to a p-value of 0.05, a higher value indicates greater significance) and the x-axis is the difference in expression between the two experimental groups as log2 fold changes (vertical sliders indicate miRNAs as either up- or down regulated above a fold change of 1.5). Highlighted in green are the most reliable (6 abundant miRNAs from set A with RF≥0.8) and in red the most informative (9 less abundant miRNAs from set B above the critical MoR value d = 0.57) biomarkers according to the MoR-method (see Figs 2 and 3).CC BY · PubMed Central
Fig 2 Reliability investigation. Plot of relative frequencies denoting for a miRNA how often among 800 MoR repeats with random subsamples of the original groups it has been crystallized as informative (original groups: controls n = 28, AD n = 22 subjects). (A) Relative frequencies of set A miRNAs with reliable biomarker candidates over the solid red line (RF = 0.8); (B) Relative frequencies of set A miRNAs with reliable biomarker candidates over the solid red line (RF = 0.8) after substitution by corresponding group means; (C) Bar diagram of the reliable biomarker signals of set A. Stars (*) over the bars point to significant p-values (MANCOVA, p < α*, where α* is Bonferroni corrected α = 0.05) and therewith to significant biomarkers.
Fig 2 Reliability investigation. Plot of relative frequencies denoting for a miRNA how often among 800 MoR repeats with random subsamples of the original groups it has been crystallized as informative (original groups: controls n = 28, AD n = 22 subjects). (A) Relative frequencies of set A miRNAs with reliable biomarker candidates over the solid red line (RF = 0.8); (B) Relative frequencies of set A miRNAs with reliable biomarker candidates over the solid red line (RF = 0.8) after substitution by corresponding group means; (C) Bar diagram of the reliable biomarker signals of set A. Stars (*) over the bars point to significant p-values (MANCOVA, p < α*, where α* is Bonferroni corrected α = 0.05) and therewith to significant biomarkers.CC BY · PubMed Central
Fig 3 Measure of Relevance for miRNA expression data in CSF. Application of the MoR approach to miRNAs of set B for identifying relevant expression differences between controls and AD cases. In the control group n = 28 and in the AD group n = 22 subjects were examined. MoR-values over the red line are to be declared as informative (critical MoR-value for the informative designation d = 0.57). Bar diagram of the most informative biomarker signals of set B. Stars (*) over the bars point to significant p-values in MANCOVA (MANCOVA, p < α*, where α* is Bonferroni corrected α = 0.05).
Fig 3 Measure of Relevance for miRNA expression data in CSF. Application of the MoR approach to miRNAs of set B for identifying relevant expression differences between controls and AD cases. In the control group n = 28 and in the AD group n = 22 subjects were examined. MoR-values over the red line are to be declared as informative (critical MoR-value for the informative designation d = 0.57). Bar diagram of the most informative biomarker signals of set B. Stars (*) over the bars point to significant p-values in MANCOVA (MANCOVA, p < α*, where α* is Bonferroni corrected α = 0.05).CC BY · PubMed Central
Fig 4 Scatter plot: Correlation of CSF miR-146a expression and levels of total tau, p-tau and Aβ1–42. Correlation significances were proven by Pearson correlation coefficients. Data were analysed applying Cq 32 as cut-off for miR-146a expression levels. Expression levels of miR-146a (2^-dCt log2) are inversely correlated with concentrations of total tau and Aβ1–42 in the AD group: (A) miR-146a expression levels vs. tau, AD cases: r = -0.5142, 98% CI -0.8065 to -0.01993, p = 0.0171; (B) miR-146a expression levels vs. Aβ1–42, AD cases: r = -0.5364, 98% CI -0.8121 to -0.06519, p = 0.0101. (C) No significant correlations were observed for concentrations of p-tau and miR-146a expression levels in the AD- and control group. Aβ1–42 = b-amyloid 42; CI = confidence interval; p-tau = phosphorylated tau.
Fig 4 Scatter plot: Correlation of CSF miR-146a expression and levels of total tau, p-tau and Aβ1–42. Correlation significances were proven by Pearson correlation coefficients. Data were analysed applying Cq 32 as cut-off for miR-146a expression levels. Expression levels of miR-146a (2^-dCt log2) are inversely correlated with concentrations of total tau and Aβ1–42 in the AD group: (A) miR-146a expression levels vs. tau, AD cases: r = -0.5142, 98% CI -0.8065 to -0.01993, p = 0.0171; (B) miR-146a expression levels vs. Aβ1–42, AD cases: r = -0.5364, 98% CI -0.8121 to -0.06519, p = 0.0101. (C) No significant correlations were observed for concentrations of p-tau and miR-146a expression levels in the AD- and control group. Aβ1–42 = b-amyloid 42; CI = confidence interval; p-tau = phosphorylated tau.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Cited by

Sorted by citations

See all 236

Related

Metadata

Authors
Denk, J., Boelmans, K., Siegismund, C., Lassner, D., Arlt, S., & Jahn, H.
Affiliations
  • University Medical Center Hamburg-Eppendorf (DE)
  • Institut Kardiale Diagnostik und Therapie (DE)
Corresponding author
Jahn, Holger
ORCID
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2015-05-20
Volume
10
Issue
5
Pages
e0126423
ISSN
1932-6203 (ISSN-L)
DOI
10.1371/journal.pone.0126423
PMC
PMC4439119
OpenAlex
W1487838396
Cited by
236
References
77
Citations by year
2026: 5 · 2025: 11 · 2024: 15 · 2023: 15 · 2022: 18 · 2021: 44 · 2020: 22 · 2019: 24 · 2018: 24 · 2017: 30 · 2016: 21 · 2015: 7
FWCI
9.04
Type
journal article
Language
en
Open access
Licence
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, miRNA expression profiling, cerebrospinal fluid, biomarkers, miR-100, miR-103, miR-375, miR-146a, microRNA expression, OpenArray, disease diagnosis, MAPT, BACE1, mTOR
MeSH terms
Aged, Alzheimer Disease, Female, Humans, Male, Middle Aged, Signal Transduction, Biomarkers, Discriminant Analysis, Aspartic Acid Endopeptidases, tau Proteins, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, MicroRNAs, Epigenesis, Genetic, Amyloid Precursor Protein Secretases, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review